Cyberounds Logo
December 12, 2018 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Central Nervous System-selective Estrogens: A Safe Estrogen Therapy
CME credit is no longer available for this conference.
Istvan Merchenthaler, M.D., Ph.D., D.Sc. and Laszlo Prokai, Ph.D., D.Sc.

Dr. Merchenthaler is a Professor, Department of Epidemiology & Preventive Medicine and Anatomy & Neurobiology, University of Maryland, School of Medicine, Baltimore, MD; and Dr. Prokai is the Robert A. Welch Professor, Department of Molecular Biology & Immunology, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, TX.

Within the past 12 months Dr. Merchenthaler received grant/research support from Ausio Pharmaceuticals, while Dr. Prokai was involved with AgyPharma, LLC, that he co-founded.

Albert Einstein College of Medicine, CCME staff and interMDnet staff have nothing to disclose.


Release Date: 06/07/2010
Termination Date: 06/07/2013

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe the mechanisms by which estrogen exerts neuroprotective effects
  • List the efforts to develop a safe estrogen therapy without side effects in the uterus and breast
  • Discuss concepts to enable safe, central nervous system-selective estrogen therapy.

 
The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity